Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 14Head & Neck 3Genitourinary 3Thoracic 2Other 2Lymphoid 2Endocrine 2Other solid neoplasm 1Gynecologic 1Dermatologic 1CNS 1Breast 1

Conditions

Neuroendocrine Tumors 532Pituitary Neoplasms 188Multiple Endocrine Neoplasia Type 1 187Thyroid Cancer, Papillary 178Pheochromocytoma 153Carcinoma, Neuroendocrine 140Thyroid Neoplasms 130Neoplasms 107Paraganglioma 99Carcinoid Tumor 99Adrenocortical Carcinoma 92Thyroid Carcinoma, Anaplastic 82Pancreatic Neoplasms 69Neoplasm Metastasis 67Insulinoma 61Adrenal Gland Neoplasms 61Carcinoma, Medullary 59Gastro-enteropancreatic neuroendocrine tumor 58Adenocarcinoma, Follicular 58Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 56Adenoma, Islet Cell 56Lung Neoplasms 50Sarcoma 49Colorectal Neoplasms 49Carcinoma, Renal Cell 49Melanoma 47Small Cell Lung Carcinoma 45Prostatic Neoplasms 44Head and Neck Neoplasms 43

Interventions

GSK3352589 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Irritable Bowel Syndrome × Endocrine × Clear all
NCT03154086 2019-08-09

A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers

GlaxoSmithKline

Phase 1 Completed
68 enrolled 80 charts
Endocrine

Multiple Endocrine Neoplasia Type 2a, Irritable Bowel Syndrome

NCT02727283 2017-05-08

A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers

GlaxoSmithKline

Phase 1 Completed
16 enrolled
Endocrine

Multiple Endocrine Neoplasia Type 2a, Irritable Bowel Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡